病例研究
记录在案的病例，
清晰呈现分析。
对癌症病例进行结构化分析｜临床背景、时间线、发现与解读，并以教育参考资料的形式呈现。
.webp&w=3840&q=75)
CS-005Not formally staged (no TNM given); mediastinal and left hilar lymph node enlargement with sigmoid colon and later left adrenal gland metastases
SMARCA4缺失型NSCLC伴罕见乙状结肠和肾上腺转移：病例报告
一名59岁男性患有SMARCA4缺失型非小细胞肺癌，出现罕见的乙状结肠和肾上腺转移，后在调整化疗联合免疫治疗方案后获得良好疗效。
Non-small cell lung cancer (NSCLC) with SMARCA4 gene deletionFrom initial presentation through post-treatment follow-up; exact duration not specified in the sourceA SMARCA4-deficient NSCLC case featuring an atypical sigmoid colon metastasis and subsequent adrenal metastasis, with disease progression on initial chemo-immunotherapy and radiotherapy followed by a favorable response to a switched gemcitabine, nedaplatin, bevacizumab, and camrelizumab regimen.
阅读病例→
CS-004Not reported in the source
CD19 CAR-T治疗使TP53突变、三线治疗难治性伯基特淋巴瘤获得持久缓解
一名16岁男性患有TP53突变型伯基特淋巴瘤，最初被误诊，并对三种化疗方案均无反应；接受CD19靶向CAR-T细胞治疗（阿基仑赛，axicabtagene ciloleucel）后达到完全代谢缓解，并在治疗30个月后仍处于缓解状态。
Burkitt lymphoma (TP53-mutated)From initial presentation through 30 months post-CAR-T infusion (latest follow-up March 2025)This case examines whether TP53-mutated, chemoresistant Burkitt lymphoma can nonetheless respond to CD19-directed CAR-T cell therapy, and what the underlying diagnostic, apoptotic, and metabolic evidence suggests about that outcome.
阅读病例→
CS-003not reported in the source
BRAF野生型甲状腺癌对帕博利珠单抗联合化疗产生持久近完全缓解
一例BRAF V600E野生型、PD-L1高表达且在酪氨酸激酶抑制剂治疗后进展的未分化甲状腺癌患者，在帕博利珠单抗联合白蛋白结合型紫杉醇和卡铂治疗下获得了持续超过30个月的近完全缓解。
Anaplastic Thyroid CancerSustained response followed for over 30 months from initiation of pembrolizumab-based triplet therapyExamines the evidence base for a sustained near-complete response to pembrolizumab combined with nab-paclitaxel and carboplatin in BRAF V600E wild-type, PD-L1-high anaplastic thyroid cancer following progression on multi-targeted tyrosine kinase inhibitor therapy.
阅读病例→
CS-002Metastatic HER2-positive breast cancer with active brain metastases (>20 lesions); no formal TNM stage reported
HER2阳性乳腺癌接受德曲妥珠单抗治疗后获得持久的颅内完全缓解
一例HER2阳性乳腺癌患者存在20余个活动性脑转移灶，在全脑放疗（WBRT）和T-DM1治疗后进展，接受德曲妥珠单抗治疗后获得颅内完全缓解，并维持超过20个月。
HER2-positive breast cancerMore than 20 months of follow-up after initiation of third-line trastuzumab deruxtecanExamines a complete and durable intracranial response to trastuzumab deruxtecan (T-DXd) as third-line therapy in a patient with HER2-positive breast cancer and more than 20 active brain metastases who had progressed after whole-brain radiotherapy and trastuzumab emtansine (T-DM1).
阅读病例→
CS-001Advanced/metastatic, chemoresistant pancreatic adenocarcinoma; specific TNM stage not reported
曲美替尼联合羟氯喹治疗KRAS突变型化疗耐药性胰腺癌的两例患者
一项两例患者的病例系列报告显示，在化疗耐药性、KRAS突变型转移性胰腺腺癌中，曲美替尼联合羟氯喹可实现疾病稳定；本文结合其潜在生物学依据和证据质量对这一结果进行考察。
KRAS-mutated advanced (metastatic) pancreatic ductal adenocarcinomaJanuary 2020 to time of publicationCase series evaluating trametinib (MEK inhibitor) combined with hydroxychloroquine (autophagy inhibitor) in two patients with KRAS-mutated, chemoresistant advanced pancreatic adenocarcinoma
阅读病例→